The Hughes Medical Institute, one of the most famous non-profit medical research institutes in the United States, has become an "angel team" research institute for the VFV virus in the global bioterrorism outbreak, and under the coordination of the WHO.

Qiu Xiang led a few members of the team and walked towards the conference room.

Qiu Xiang now has a report in his hand, a report on VFV antibody research, but everyone's faces are not too happy.

Antibodies in a patient's serum or body fluids are the most tried and tested method for viral infections. During this period of research, the team found that the antibodies in the patient's serum were too weak to clear the VFV virus.

And they can't find a patient who is convalescent, because the VFV virus is so virulent that the antibodies produced by the human body's immune system can't 'kill' the virus at all.

This has led to their research on specific drugs, which is at a loss.

After discussion, the team decided to try animal immunization serum, and found 8 animals to experiment with the virus in animals, but soon found that even after immunization, bovine serum had no obvious effect on the treatment of VFV.

During this time, I experimented every day and tried hundreds of possible ways.

After trying all the possible conjectures they discussed, they found that the monoclonal antibody had the best chance of success.

In order to speed up the research, the team of 72 people was divided into eight groups, four groups were responsible for finding other therapeutic drugs, and the remaining four groups were responsible for testing the 16 monoclonal antibodies that had been researched, and the team led by Qiu Xiang was one of them.

During the test, all four groups used 1,000 times the LD50 (half lethal dose) to poison the experimental mice.

Within 24 hours after infection, mice were injected with monoclonal antibodies, and 16 monoclonal antibodies were injected into four groups, and the remaining 11 were effective. 48 hours, 5 antibodies are still effective; After 72 hours, only two antibodies remained.

It was an antibody that the first team led by him and the third team led by the British medical scientist Judson studied an antibody.

Finding two of the antibodies, they began to try to experiment with rabbits, and for 24 hours, both antibodies were effective; After 48 hours, the ability of monoclonal antibodies began to show significant differences, many of them lost their activity, and the effect of the antibodies became weaker and weaker for a long time.

The incubation period of the VFV virus is far beyond this time, and such antibodies cannot be used for treatment at all, and research has come to a halt again.

Finally, after discussion, it was decided to use the 'cocktail' method in the study of EBOR's specific drug, using the best four monoclonal antibodies to mix, and using a virus that can produce human interferon as an adjuvant for the "cocktail" antibody, so that the "cocktail" can still play a role after 72 hours of infection.

And the 'cocktail' potion was named AG72 by them.

And now, the AG72 test result is in Qiu Xiang's hands.

Looking at the report in his hand, he couldn't be happy, because the result was different from what they had imagined.

Qiu Xiang, Judson and the others entered the conference room, and they felt dozens of pairs of eyes fall on them. Many researchers on the field did not look very good. Since the formation of the 72-member team, their research has made some progress, but not much progress, and now hope that it will be in the report in the hands of Qiu Xiang and Judson.

"Come on." Qiu wanted to hand the report to Judson.

"Here you go." Judson shook his head and didn't reach for it.

Qiu Xiang nodded helplessly, and when everyone was seated, he asked the assistant to send the report in his hand to every researcher on the field, and walked to the podium by himself.

"The test results for the monoclonal antibody came out, which was different from what we predicted. We tested the effect of AG72 with two rhesus macaques. On the 4th day of infection, the monkeys developed symptoms and were given AG72 as planned. But unfortunately, the virus in the monkey did not disappear, and VFV was not cured. Qiu Xiang's voice was heavy.

There was a sigh in the conference room, and many experts shook their heads with sad faces.

Monoclonal antibodies are the most promising direction for success in a short period of time, and if monoclonal antibodies fail, specific drugs will appear for a longer time.

Now the number of people infected with VFV virus in the world has reached more than 26,000, and the number is refreshing every day, and the death toll has soared to 2,378, and there is no cure for the time being. If the treatment is not available, it means that the number of deaths will increase.

"But there's not too good news."

Everyone instantly cheered up and pricked up their ears to wait for Qiu Xiang's answer.

"Rhesus macaques injected with AG72, within a week, 72 could not cure the condition of VFV, but it could inhibit VFV metabolism and control the further deterioration of the disease. This result can buy more time for the treatment of the disease. ”

Many people on the field applauded excitedly and cried with joy, at this time, any small good news is exciting good news.

The 'Angel Team' has made a breakthrough in the specific drug of VFV virus, and successfully developed a monoclonal antibody drug to inhibit the deterioration of VFV.

When the news was released, it spread to all corners of the world like crazy, attracting the excitement of the whole people.

Now is the worst period of the VFV virus, in the midst of a global panic, and the biological virus has almost reached a tipping point of complete loss of control. At this time, the good news from the 72-person team is undoubtedly the most exciting time.

There is light at the end of the tunnel for victory in the war against biology.

While the outside world was cheering for the results of the 72-member team, there was the same joy in another corner.

Jianghe Institute of Microbial Medicine.

Xu Minsheng had a rare smile on his face.

After Jianghe and Lanhong Pharmaceutical were merged by the marching ant group and reorganized into Jianghe Pharmaceutical, he became one of the team leaders of Jianghe Pharmaceutical's drug development, responsible for the development of tumor vaccines.

The current headquarters of Jianghe Pharmaceutical is the main microbial medical research institute of Haixing Company, and the main drugs of Haixing Company are developed from here.

Some time ago, Chen Mo contacted them, told them a research direction, and also gave them some information, so that the team of their research institute could produce drugs related to the data, which may reduce the activity of VFV virus and help VFV treatment.

Now is the most terrifying time when the VFV virus is raging, and after receiving Chen Mo's order, the team of the entire research institute immediately gathered personnel and began to develop the drug.

The team concentrated the strength of the elite personnel of the entire research institute, thoroughly ate the information given by Chen Mo, worked in shifts to study, and finally made progress.

During this period, he contacted Chen Mo several times and asked some questions about the research direction, and after several major breakthroughs, he finally completed the required medicine according to Chen Mo's meaning.

They named the drug they developed, HX3.

At present, the metabolic activity of VFV virus in the petri dish is significantly reduced in 24 hours after adding the agent of HX3, and the agent has met Chen Mo's requirements.

"It worked." Xu Minsheng showed a rare smile.

"It worked." Several of the surrounding researchers also nodded their heads and let out a deep breath.

"You put the report together and give it to the boss. I'm going to ask my boss what to do with the HX3 next. After speaking, Xu Minsheng turned around and left the laboratory.